You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

46 search results for: CRSwNP

IRS-ISIAN 2024 | Guideline Definitions of Control in <b>CRSwNP</b>

expert video

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

5 min

Rhinology

Prof. Peter Hellings explores the concept of disease control in CRSwNP.

The Pathophysiology of Type 2 Inflammation in <b>CRSwNP</b>

interactivity

The Pathophysiology of Type 2 Inflammation in CRSwNP

5 min

Rhinology

Learn how type 2 inflammation underlies the pathophysiology of CRSwNP

Comparative Efficacy of Biologics for Patients with Uncontrolled and/or Severe <b>CRSwNP</b>

expert video

Comparative Efficacy of Biologics for Patients with Uncontrolled and/or Severe CRSwNP

7 min

Rhinology

Prof. Peter Hellings presents the comparative efficacy of biologics for patients with uncontrolled and/or severe CRSwNP.

From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe <b>CRSwNP</b>

expert video

From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

9 min

Rhinology

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP.

Why did the definition of control in <b>CRSwNP</b> change between EPOS 2020 and EPOS/EUFOREA 2024?

expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

5 min

Rhinology

Prof. Hellings and Prof. Corso discuss the significance and rationale behind the new definition of CRSwNP.

expert video

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

9 min

Rhinology

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP

Partnering With Patients for Clinical Decision-Making in <b>CRSwNP</b>

expert video

Partnering With Patients for Clinical Decision-Making in CRSwNP

2 min

Rhinology

Profs. Wytske Fokkens and Joaquim Mullol investigate the importance of partnering with patients with CRSwNP in clinical decision-making.

expert video

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

29 min

Pulmonology

Join global experts for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in <b>CRSwNP</b>?

expert video

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

5 min

Rhinology

Prof. Hellings and Prof. Corso explore the time frame to assess if the patient with CRSwNP has achieved remission

What contributes more to loss of smell in patients with <b>CRSwNP</b>: nasal obstruction or inflammation?

expert video

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

5 min

Rhinology

Prof. Mullol discusses the contribution of nasal obstruction and inflammation in loss of smell in patients with CRSwNP

Podcast

ADVENT On Air | Loss of Smell in CRSwNP Patients

15 min

Rhinology

Profs. Wytske Fokkens and Joaquim Mullol discuss the clinical significance of the loss of smell in patients with CRSwNP.

Expert Discussion: Partnering With Patients to Improve <b>CRSwNP</b> Outcomes

expert video

Expert Discussion: Partnering With Patients to Improve CRSwNP Outcomes

15 min

Rhinology

Prof. Hellings discusses the importance of partnering with patients and considering the clinical importance of symptom improvements.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ChinaChange country/region